NewTimeSpace News: By the close of trading on Jul 8, 2026, EACON(07687.HK) saw a gain of 9.99% in its share price, closing at HKD 96.7. During the session, it reached an intraday high of HKD 101.2 and touched an intraday low of HKD 88.05.
NewTimeSpace News: Hong Kong Johnson Holdings Co., Ltd. (01955.HK) announced on 8 July that it has secured multiple security and cleaning service contracts totalling around HK$230 million. The portfolio includes a three-year security contract for government cultural venues worth HK$100 million, a two-year residential estate security contract valued at HK$40 million, and a campus cleaning contract for a renowned local university at HK$90 million. The Group plans to deploy electric vehicles on campus to cut carbon emissions. Contract values are subject to adjustments per contractual terms. The Group views these wins as market recognition of its service standards and a boost to its market standing.
NewTimeSpace News: Shanghai Biren Technology Co., Ltd. (06082.HK) announced on 8 July that the placing of new H-shares under the general mandate has been completed. A total of 153,000,000 placing shares were successfully allotted to no fewer than six placees at a placing price of HK$46.20 per share, generating estimated net proceeds of around HK$7.038 billion after deducting commissions and estimated expenses. The placing shares account for approximately 5.90% of the total enlarged issued share capital, and all placees are independent third parties. The Company’s registered capital and total number of issued shares have been adjusted accordingly.
NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that the Phase I clinical trial of HLX05-N, its self-developed cetuximab injection biosimilar, has completed first patient dosing in Chinese Mainland for patients with metastatic colorectal cancer (mCRC). Global sales of cetuximab injection reached approximately USD1.658 billion in 2025 based on IQVIA data. The IND applications for the Phase I trial of HLX05-N were approved by NMPA and the FDA in April and May 2026 respectively. Investors are reminded of uncertainties in drug research and development.
NewTimeSpace News: China Feihe announced on July 8 that its wholly-owned subsidiary Heilongjiang Feihe subscribed to financial products issued by SPD Bank using idle funds, with an aggregate principal amount of RMB 300 million and an expected annual yield of 2.30%.
NewTimeSpace News: Agile Group Holdings Limited (03383.HK) announced that total contracted sales of the Group, together with its joint ventures, associates and Agile-branded projects, reached approximately RMB820 million in June 2026, corresponding to a gross floor area (GFA) of around 127,000 square metres. For the six months ended 30 June 2026, cumulative contracted sales totalled approximately RMB3.8 billion, with a corresponding GFA of roughly 408,000 square metres.
NewTimeSpace News: 361 Degrees announced on July 8 that Ms. Ferheen Mahomed has resigned as an independent non-executive director and ceased to be a member of the nomination committee. On the same day, the Board appointed Ms. Chan Yee Fong as an independent non-executive director, who will serve as a member of the audit committee, nomination committee and remuneration committee.
NewTimeSpace (newtimespace.com) reported that on July 8, 2026, the chip theme strengthened, with SMIC (00981.HK) surging in volatile trading. As of 13:34, the stock was quoted at HKD 77.550, up 5.58%.
NewTimeSpace (newtimespace.com) reported that on July 8, 2026, the humanoid robot theme continued to weaken. UBTECH (09880.HK) extended its decline, with the stock quoted at HKD 89.100 as of 13:20, down 4.55%.
NewTimeSpace News: Shandong Boan Biotechnology Co., Ltd. (06955.HK) announced on 8 July that the Investigational New Drug (IND) application for BA1203, a masked PD-1/IL-2 antibody-cytokine prodrug under development, has been accepted by the Center for Drug Evaluation (CDE) of NMPA for the treatment of solid tumours. The candidate integrates PD-1 blockade and local IL-2 immune activation, with preclinical data demonstrating superior anti-tumour potency and favourable safety profiles versus existing PD-1 inhibitors. To the Company’s knowledge, BA1203 will be the first masked PD-1/IL-2 antibody-cytokine retaining IL-2Rα binding activity to enter clinical development in China. The Company reminds investors of uncertainties in drug R&D progress.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary Chia Tai Tianqing has further deepened its exclusive strategic partnership with GlaxoSmithKline (GSK), obtaining the commercialisation rights for two flagship innovative respiratory drugs of GSK in mainland China: Trelegy Ellipta® (fluticasone furoate/umeclidinium bromide/vilanterol powder for inhalation) and Anoro Ellipta® (umeclidinium bromide/vilanterol powder for inhalation). All sales revenue generated from the two products will be recognised as operating revenue of Chia Tai Tianqing.
NewTimeSpace News: On 8 July 2026, BIDU-SW(09888.HK) trended upward during morning trading. As of 11:35, the stock was quoted at HK$116.6, up 5.42%. Overseas research institute AutnmyAI released a global ranking of overall Robotaxi competitiveness, with Baidu Apollo Go claiming the top spot by composite score worldwide.
NewTimeSpace (newtimespace.com) News, SKB BIO (06990.HK) plans to issue in total 5.84 million shares by placement, with estimated net proceeds of HKD 2.72 billion.
NewTimeSpace News: InSilico Medicine Cayman TopCo (03696.HK) announced on 8 July that Rentosertib (ISM001-055), an AI-driven TNIK small-molecule inhibitor, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The trial plans to enrol 320 subjects across 47 clinical centres nationwide, with the primary endpoint being the annual rate of decline in forced vital capacity within 52 weeks. The asset has previously obtained FDA Orphan Drug Designation and NMPA Breakthrough Therapy Designation. The Company cautions uncertainties over business development.
NewTimeSpace News: Zhong Ji Longevity Science Group Limited (00767.HK) announced on 7 July that its wholly-owned subsidiary Shenzhen Zhongji Health Science Co., Limited signed a memorandum of understanding with Shenzhen Zhongtou Huijin Fund Management Co., Ltd. to jointly set up a special M&A fund for the healthcare industry with a proposed size of RMB1 billion, to be raised in three tranches. The fund will target investments in longevity science, cell therapy, anti-ageing biomedicine and premium health management industries. The memorandum is non-binding and the cooperation is subject to further formalisation.
NewTimeSpace News: Chery Automobile Co., Ltd. (09973.HK) announced on 7 July that it entered into an automobile sales framework agreement with Guangdong Ruixun Automobile Sales Service Co., Ltd. The annual caps are RMB250 million for 2026, RMB500 million for 2027 and RMB800 million for 2028, aggregating RMB1.55 billion. Controlled by Ms. Wang Laichun, the Company’s Non-executive Director, Guangdong Ruixun gives rise to continuing connected transactions. Pricing terms will not be more favourable than those offered to independent third parties. The Group intends to expand domestic market coverage via Ruixun’s sales network.
